IN TIMES OF COVID19, CANCER PATIENTS HAVE A NEW WAY TO AVOID DELAYING DIAGNOSTIC PROCEDURES AND SURVEILLANCE OF BLADDER TUMOURS.

Concerned about the postponement of surveillance procedures and the increased risk of contamination in Hospitals, a team of researchers from Ipatimup and the Institute for Research and Innovation in…


TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients

Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic…


Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder…


Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study

The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300…


Article on "Vida Economica" Newspaper

Uromonitor was highlighted on a portuguese paper. Non-invasive and low cost were two of the advantages mentioned on the article.


Prize Entrepreneurs of the everis foundation

The president of the Everis Foundation, Eugenio Galdón, has awarded the Everis Prize 2015 to Hugo Prazeres for his Uromonitor project, a non-invasive test to detect bladder cancer by using a…